Prestige Consumer Healthcare (PBH) Q4 2026 earnings review
M&A Engine Reignited as Supply Chain Stumbles Drag Down Q4
Prestige Consumer Healthcare wrapped up a difficult FY26 characterized by chronic supply constraints for its Clear Eyes brand and Middle East shipping disruptions. Q4 revenue fell 5.0% YoY to $281.6 million, driving Adjusted EPS down 6.8% to $1.23. Despite the organic top-line weakness, the company generated robust Free Cash Flow of $246.4 million for the year. The narrative is decisively shifting from supply chain firefighting to M&A-driven growth, highlighted by the newly announced $150 million acquisition of LaCorium Health and the pending Breathe Right deal. FY27 guidance targets $1.1B+ in base revenue, indicating a slow organic recovery while awaiting M&A integration.
🐂 Bull Case
FY26 Free Cash Flow of $246.4M enabled $156M in share repurchases (2.3 million shares) while maintaining a healthy 2.6x leverage ratio. The asset-light cash conversion engine remains fully intact.
The acquisitions of Breathe Right and LaCorium Health add strong category leaders to the portfolio. LaCorium brings $40M in trailing revenue and international diversification (75% of sales in Australia).
🐻 Bear Case
Chronic Clear Eyes constraints continued to drag down North American sales (-5.8% YoY in Q4). While Pillar5 was acquired to fix this, full normalization remains an ongoing headwind into FY27.
Both Q4 (-6.8%) and full-year FY26 (-3.1%) saw Adjusted EPS declines, proving that aggressive share buybacks couldn't entirely mask the operational disruptions.
⚖️ Verdict: ⚪
Neutral. The underlying cash generation is undeniable, but management is heavily reliant on newly acquired supply chain (Pillar5) and unclosed M&A (LaCorium, Breathe Right) to restore growth after a year of operational stumbles.
Key Themes
Eye Care Supply Chain Hangover
The Pillar5 acquisition was supposed to fix the Clear Eyes supply issue, yet Q4 North American OTC revenue still dropped from $248.9M to $234.5M. Rebuilding retail safety stock and regaining lost shelf space will carry into FY27, creating significant execution risk for the core portfolio.
International Disruptions and Macro Headwinds
International OTC revenues dropped in Q4 to $47.1M due to shipping disruptions in the Middle East and lower eye care supply. Management explicitly acknowledged a 'volatile consumer backdrop,' pointing to continued macroeconomic pressures impacting consumer purchasing behavior globally.
M&A Integration Execution Risk
The company is taking on three major integrations simultaneously: Pillar5 (a manufacturing facility), Breathe Right, and LaCorium. While LaCorium adds $40M in revenue, running multiple integrations concurrently strains management focus. Notably, Q4 Adjusted Net Income already required normalization for costs associated with optimizing the Pillar5 facility—a clear contradiction to the narrative that these acquisitions will be seamless.
E-Commerce and GI Category Momentum
E-commerce continues its rapid ascent, structurally altering the company's distribution mix. GI brands like Fleet, Dramamine, and Hydralyte are driving the core business forward, effectively offsetting the eye care weakness in alternative channels.
LaCorium Health Acquisition
PBH is acquiring Australian therapeutic skin care leader LaCorium for ~$150M. It brings a portfolio of #1 and #3 brands (Dermal Therapy, Flexitol) in lip and foot care, delivering a highly synergistic asset-light model that immediately scales the international segment with expected double-digit net sales growth in calendar 2026.
Aggressive Share Repurchases
In FY26, PBH opportunistically repurchased 2.3 million shares for ~$156 million. Armed with $246.4M in Free Cash Flow, the company is using its balance sheet to engineer per-share value and support the stock price while waiting for operational headwinds to clear.
AI Adoption in E-Commerce
Management highlighted leveraging AI adoption to optimize digital content in response to rapidly changing consumer behavior. This technological modernization has been a direct catalyst in pushing E-Commerce to 18% of total FY26 revenue, up 4.5x since FY19.
Other KPIs
Decelerating. Q4 adjusted gross margin compressed nearly 200 bps year-over-year from 57.3% to 55.4%. This indicates negative operating leverage, driven by lower volumes and manufacturing overhead absorption issues at the newly acquired Pillar5 facility.
Stable. FCF increased slightly from $243.3M in FY25. This underscores the asset-light, high-cash-conversion nature of the business model, which comfortably funded the $156M buyback program and positioned the balance sheet for the upcoming LaCorium cash acquisition.
Guidance
Accelerating. The midpoint implies ~2% reported growth over FY26's $1,088.7M, representing a return to expansion. Crucially, this outlook explicitly excludes the pending Breathe Right and LaCorium acquisitions, meaning ultimate reported growth will step up significantly once those deals close.
Accelerating. After a year of negative organic growth driven by Clear Eyes shortages, management expects a modest return to historical target algorithms as supply normalizes and E-commerce expansion continues.
Accelerating. Reversing the contraction seen in FY26 ($4.38). The midpoint ($4.465) represents roughly 2% YoY growth. Management notes this target bakes in the ongoing costs associated with the Pillar5 manufacturing optimization.
Stable. Modest growth from the $246.4M delivered in FY26, supporting the narrative of rapid deleveraging post-acquisitions. Management projects approaching $900 million in aggregate FCF over the next three years.
Key Questions
M&A Integration Bandwidth
With three acquisitions closing in close succession (Pillar5, Breathe Right, LaCorium), what is the specific timeline for realizing anticipated cost synergies, and how are you ensuring the internal bandwidth exists to integrate a manufacturing facility alongside two separate brand portfolios?
LaCorium Margin Profile
The LaCorium acquisition is expected to generate $12M in EBITDA on $40M in revenue (a 30% margin). How does this margin profile compare to your core International segment, and what are the specific U.S. cross-selling opportunities for the Flexitol and Crampeze brands?
Middle East Shipping Disruptions
Q4 saw shipping disruptions in the Middle East noticeably impacting the International segment. Are these logistical issues resolved, or is ongoing friction built into the 1-3% organic growth guidance for FY27?
AI Conversion Metrics
You noted leveraging AI for E-commerce content optimization. Can you quantify the conversion rate lift you are seeing from these AI tools compared to traditional content strategies across platforms like Amazon?